作者: Ka-On Lam , Victor Ho-Fun Lee
关键词:
摘要: Colorectal cancer remains a major cause of morbidity and mortality worldwide despite substantial improvement in the standard care. Although surgical resection selected patients may potentially be curative, systemic therapy is only choice treatment for most with metastatic colorectal cancer. Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody has established its role through multiple well-designed clinical trials yet, optimal use anti-EGFR undefined. This article serves to review available evidence antibodies speculate strategy their uses.